An investigational drug known as APT102 significantly reduced damage to heart muscle from a heart attack and minimized the risk of bleeding during follow-up treatments, according to an animal study based on a decade of work by APT Therapeutics, scientists at Washington University School of Medicine in St. Louis and colleagues at Cornell and Harvard.
Standard heart attack treatment often causes heart tissue damage. Once the blood clot that causes a heart attack is removed from an artery, molecules from dead and dying cells mix with blood rushing back through the artery. One of these molecules, adenosine triphosphate (ATP), is inflammatory; another, adenosine diphosphate (ADP), causes more clotting.
“ATP and ADP have different roles, but they both lead to more heart damage as they flood through the reopened artery after a heart attack,” said senior author Dana Abendschein, PhD, associate professor of medicine and of cell biology and physiology at Washington University.
APT102, invented and patented by APT Therapeutics, is a genetically-engineered version of the human protein apyrase, which transforms ATP and ADP into a benign molecule, adenosine monophosphate. Another enzyme changes this molecule into adenosine, which is beneficial for the heart.
“Adenosine opens the blood vessels, increases blood flow and also has a protective effect on the lining of the vessels,” said Abendschein. “It takes the bad products away and produces a good byproduct that’s protective.”
The scientists treated 21 dogs for the study. After the clots that caused their heart attacks were dissolved using medication, eight received the standard post heart-attack drug clopidogrel, a blood thinner; seven were given low doses of APT102; and six were given high doses of APT102.
The researchers found that treatment with APT102 significantly reduced the amount of irreversible heart muscle damage.
“That’s a huge benefit because the majority of patients who have a lot of heart muscle damage go on to have heart failure,” Abendschein said.
By breaking down the clotting factor ADP, treatment with APT102 also eliminated the return of the clots, which can lead to further heart damage.
“Virtually every agent that’s being used in patients now to prevent clot formation blocks the blood clotting agents known as platelets, and that creates a risk of bleeding,” Abendschein said. “This is not true of APT102.”
Other anticlotting agents have to be digested and converted into their active form in the liver, but APT102 can be injected directly into a vein, where it works immediately.
“When it comes to heart attack treatment, the saying is ‘time is muscle’ — the longer you delay treatment, the more irreversible damage the heart will suffer,” Abendschein said. “APT102 may help us save critical time by letting treatment start right away.”
The researchers hope to start clinical trials of the drug in people within the next year.
Citation: Moeckel D, Jeong SS, Sun X, Broekman MJ, Nguyen A, Drosopoulos JHF, Marcus AJ, Robson SC, Chen R, Abendschein D. Optimizing human apyrase to treat arterial thrombosis and limit reperfusion injury without increasing bleeding risk. Science Translational Medicine, Aug. 6, 2014.
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- Kudos To "The Independent" Newspaper For Debunking Nibiru "Blood Moon" Hoax
- USDA Microbiologist Warns Bacteria In Vaping Products May Be A Health Concern
- Your Microbiome Did Not Cause Your Weight Problem
- 20 Cent School Intervention Stops Unhealthy Weight Gain In Children
- Gödel,Frenkel, Kurzweil, and Hawkins on AI
- Control Cancer By Making The Tumor Cell Environment Hostile
- A Great Blitz Game
- "So your absolutely certain and can absolutely guarantee that its not real mr walker. Charles ..."
- "Great, glad to have helped Michael, thanks :)...."
- "Right. But it can help to pin that down a bit and say what particularly you are worried about...."
- "Interesting Thanks for the helpful information, Robert. You give such insightful and easy to understand..."
- "Okay - there are a lot of urban myths about earthquakes, and these Nibiru people tend to..."
- Breast Cancer: Genomics May Show Where Chemo Might Not Be Needed
- Gallup Poll: Great Example of How to Bias a Social Science Study
- Another Kardashian Craze Debunked
- Fad Friday: Ditch The Body Wrap!
- Commonly Cited Stat of 10 Bacteria for Every 1 Human Cell Is Wrong
- Why The EpiPen And Other Generic Drugs Are So Expensive
- Heart failure in the elderly set to triple by 2060
- Up to 80 percent of heart failure patients denied therapy to reduce hospitalization and death
- Increased risk of death for heart failure patients with each NHS hospital admission
- Nebivolol prevents anthracycline-induced cardiotoxicity
- Traffic accidents increased by 50 percent in patients with implantable cardioverter defibrillator